keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis B antiviral therapy

keyword
https://www.readbyqxmd.com/read/29785021/advanced-septa-size-quantitation-determines-the-evaluation-of-histological-fibrosis-outcome-in-chronic-hepatitis-b-patients
#1
Bingqiong Wang, Yameng Sun, Jialing Zhou, Xiaoning Wu, Shuyan Chen, Shanshan Wu, Hui Liu, Tailing Wang, Xiaojuan Ou, Jidong Jia, Hong You
Hepatitis B (HBV)-related fibrosis can be reversed after effective antiviral therapy. However, detailed changes of collagen characteristics during fibrosis regression remain unclear. Paired biopsy samples obtained from chronic hepatitis B patients were imaged with second harmonic generation/two photon excitation fluorescence (SHG/TPEF)-based microscopy to identify and quantify collagen features in portal, septal, and fibrillar areas. According to the changes of Ishak stage and qFibrosis score, a total of 117 patients with paired liver biopsy appeared to have four different outcomes after 78-week antiviral therapy: fast reverse (9%), reverse (63%), stable (15%), or progress (13%) on fibrosis...
May 21, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29778254/long-term-liver-disease-treatment-and-mortality-outcomes-among-17-000-persons-diagnosed-with-chronic-hepatitis-c-virus-infection-current-chronic-hepatitis-cohort-study-status-and-review-of-findings
#2
REVIEW
Anne C Moorman, Loralee B Rupp, Stuart C Gordon, Yuna Zhong, Jian Xing, Mei Lu, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Eyasu H Teshale, Philip R Spradling, Scott D Holmberg
Chronic Hepatitis Cohort Study (CHeCS) publications using data from "real-world" patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29777955/perspectives-and-limitations-for-nucleo-t-side-analogs-in-future-hbv-therapies
#3
REVIEW
Massimo Levrero, Miroslava Subic, Francois Villeret, Fabien Zoulim
The latest generation of nucleo(t)side analogs (NAs) provide robust virus suppression with high barrier to resistance. Long term NAs treatment is associated with a partial restoration in HBV-specific T-cell functions, regression of fibrosis, no disease progression and a reduction of HCC risk but rarely lead to cure and life-long treatments is often required. New insights into the hepatitis B viral life cycle and the host immune response have expanded the potential targets for drug therapies with interesting antiviral candidates and novel immunotherapeutic approaches in early stage development...
May 16, 2018: Current Opinion in Virology
https://www.readbyqxmd.com/read/29772748/drug-delivery-strategies-for-antivirals-against-hepatitis-b-virus
#4
REVIEW
Latavia Singh, Sunaina Indermun, Mershen Govender, Pradeep Kumar, Lisa C du Toit, Yahya E Choonara, Viness Pillay
Chronic hepatitis B virus (HBV) infection poses a significant health challenge due to associated morbidity and mortality from cirrhosis and hepatocellular cancer that eventually results in the breakdown of liver functionality. Nanotechnology has the potential to play a pivotal role in reducing viral load levels and drug-resistant HBV through drug targeting, thus reducing the rate of evolution of the disease. Apart from tissue targeting, intracellular delivery of a wide range of drugs is necessary to exert a therapeutic action in the affected organelles...
May 17, 2018: Viruses
https://www.readbyqxmd.com/read/29770355/host-regulated-hepatitis-b-virus-capsid-assembly-in-a-mammalian-cell-free-system
#5
Kuancheng Liu, Jianming Hu
The hepatitis B virus (HBV) is an important global human pathogen and represents a major cause of hepatitis, liver cirrhosis and liver cancer. The HBV capsid is composed of multiple copies of a single viral protein, the capsid or core protein (HBc), plays multiple roles in the viral life cycle, and has emerged recently as a major target for developing antiviral therapies against HBV infection. Although several systems have been developed to study HBV capsid assembly, including heterologous overexpression systems like bacteria and insect cells, in vitro assembly using purified protein, and mammalian cell culture systems, the requirement for non-physiological concentrations of HBc and salts and the difficulty in manipulating host regulators of assembly presents major limitations for detailed studies on capsid assembly under physiologically relevant conditions...
April 20, 2018: Bio-protocol
https://www.readbyqxmd.com/read/29769038/impact-of-new-daa-therapy-on-real-clinical-practice-a-multicenter-region-wide-cohort-study
#6
Simone Lanini, Paola Scognamiglio, Alessandra Mecozzi, Lorella Lombardozzi, Vincenzo Vullo, Mario Angelico, Antonio Gasbarrini, Gloria Taliani, Adolfo Francesco Attili, Carlo Federico Perno, Adriano De Santis, Vincenzo Puro, Fabio Cerqua, Gianpiero D'Offizi, Adriano Pellicelli, Orlando Armignacco, Francesco Saverio Mennini, Massimo Siciliano, Enrico Girardi, Vincenzo Panella, Giuseppe Ippolito
BACKGROUND: Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs. METHODS: The study was designed as a multicenter cohort: a) to assess the evolution of treatment during the first 24 months of the activity of the Clinical Network; b) to report overall efficacy of treatments; c) to analyze potential factors associated with lack of virological response at 12 weeks after therapy (SVR12); d) to evaluate the variation of ALT at baseline and 12 weeks after therapy in those who achieved SVR12 in comparison to those who did not...
May 16, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29761102/reactivation-of-a-vaccine-escape-hepatitis-b-virus-mutant-in-a-cambodian-patient-during-anti-hepatitis-c-virus-therapy
#7
Dahlene N Fusco, Lilia Ganova-Raeva, Yury Khudyakov, Lili Punkova, Aisha Mohamed, Scarlett Se Yun Cheon, Prapti Koirala, Karin L Andersson, Gonzague Jourdain, Camille Sureau, Raymond T Chung, Georg Lauer
A 76-year-old Cambodian man co-infected with hepatitis B virus (HBV) and hepatitis C virus (HCV) 6c-1 presented for care. HBV DNA was intermittently detectable despite anti-HBs levels being above the protective threshold. During treatment for HCV, HBV DNA levels increased. Sequencing revealed multiple mutations including vaccine escape mutation and mutations predicted to enhance fitness. This case represents exacerbation of an HBV vaccine escape mutant during a direct-acting antiviral therapy.
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29758235/innovation-and-trends-in-the-development-and-approval-of-antiviral-medicines-1987-2017-and-beyond
#8
REVIEW
Shuvam Chaudhuri, Julian A Symons, Jerome Deval
2017 marked the 30th anniversary of the approval of zidovudine (AZT) as the first HIV/AIDS therapy. Since then, more than eighty antiviral drugs have received FDA approval, half of which treat HIV infection. Here, we provide a retrospective analysis of approved antiviral drugs, including therapeutics against other major chronic infections such as hepatitis B and C, and herpes viruses, over the last thirty years. During this time, only a few drugs were approved to treat acute viral infections, mainly influenza...
May 15, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29753085/effects-of-virologic-response-to-treatment-on-short-and-long-term-outcomes-of-patients-with-chronic-hbv-infection-and-decompensated-cirrhosis
#9
Jeong Won Jang, Jong Young Choi, Young Seok Kim, Jeong-Ju Yoo, Hyun Young Woo, Sung Kyu Choi, Chung Hwan Jun, Chang Hyeong Lee, Joo Hyun Sohn, Won Young Tak, Yu Rim Lee, Kwang-Hyub Han
BACKGROUND & AIMS: Little is known about the effects of antiviral therapy on short- and long-term survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis. We aimed to determine whether a maintained virologic response (MVR, defined as persistent undetectable HBV DNA during therapy) associates with short-term (6-month) and long-term (6-120 months) survival of patients with decompensated cirrhosis. METHODS: We performed a 10-year observation analysis using data from the Epidemiology and Natural History of Liver Cirrhosis study of patients with decompensated liver cirrhosis in Korea...
May 9, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29751272/overcoming-immune-tolerance-in-chronic-hepatitis-b-by-therapeutic-vaccination
#10
REVIEW
Claudia Dembek, Ulrike Protzer, Michael Roggendorf
The currently used nucleoside analogs (i.e. entecavir and tenofovir) with high barrier-to-resistance efficiently suppress viral replication, limit inflammation and reduce the sequelae of chronic hepatitis B, but cannot cure the disease and thus have to be applied long-term. Therapeutic vaccination as an approach to cure chronic hepatitis B has shown promising pre-clinical results, nevertheless the proof of its efficacy in clinical trials is still missing. This may be partially due to suboptimal vaccine design...
May 8, 2018: Current Opinion in Virology
https://www.readbyqxmd.com/read/29743799/advances-in-hcv-and-cryoglobulinemic-vasculitis-in-the-era-of-daas-are-we-at-the-end-of-the-road
#11
REVIEW
Chalermrat Bunchorntavakul, Robert Mitrani, K Rajender Reddy
Hepatitis C Virus (HCV)-related Mixed Cryoglobulinemia (MC) is a unique condition with complex pathogenesis that involves HCV antigen-driven B-lymphocyte clonal proliferation and mutagenesis. Clinical spectrum of MC ranges from asymptomatic state to clinically-apparent vasculitis involving multiple organs. In the era of Direct-Acting Antiviral (DAA) therapy, patients with HCV-related MC achieve high rates of viral clearance that is commonly accompanied by an improvement in clinical symptoms as well as immunological profiles...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29743015/mortality-trends-among-people-with-hepatitis-b-and-c-a-population-based-linkage-study-1993-2012
#12
Maryam Alavi, Jason Grebely, Behzad Hajarizadeh, Janaki Amin, Sarah Larney, Matthew G Law, Jacob George, Louisa Degenhardt, Gregory J Dore
BACKGROUND: This study evaluated cause-specific mortality trends including liver-related mortality among people with a hepatitis B virus (HBV) and hepatitis C virus (HCV) notification in New South Wales, Australia. METHODS: Notifications 1993-2012 were linked to cause-specific mortality records 1993-2013. RESULTS: Among 57,929 and 92,474 people with a HBV and HCV notification, 4.8% and 10.0% died since 1997. In early 2010s, 28% and 33% of HBV and HCV deaths were liver-related, 28% and 17% were cancer-related (excluding liver cancer), and 5% and 15% were drug-related, respectively...
May 9, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29740199/is-it-possible-to-stop-nucleos-t-ide-analogue-treatment-in-chronic-hepatitis-b-patients
#13
REVIEW
Elia Moreno-Cubero, Robert T Sánchez Del Arco, Julia Peña-Asensio, Eduardo Sanz de Villalobos, Joaquín Míquel, Juan Ramón Larrubia
Chronic hepatitis B (CHB) remains a challenging global health problem, with nearly one million related deaths per year. Nucleos(t)ide analogue (NA) treatment suppresses viral replication but does not provide complete cure of the hepatitis B virus (HBV) infection. The accepted endpoint for therapy is the loss of hepatitis B surface antigen (HBsAg), but this is hardly ever achieved. Therefore, indefinite treatment is usually required. Many different studies have evaluated NA therapy discontinuation after several years of NA treatment and before HBsAg loss...
May 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29738637/risk-of-hbv-reactivation-with-direct-acting-antivirals-against-hcv-a-cohort-study-from-egypt-and-meta-analysis-of-published-data
#14
Mohamed El Kassas, Yusuke Shimakawa, Zainab Ali-Eldin, Anna-Louise Funk, Mohamed Naguib Wifi, Samy Zaky, Fathiya El-Raey, Gamal Esmat, Arnaud Fontanet
BACKGROUND & AIMS: Hepatitis B virus (HBV) reactivation in chronic hepatitis C (CHC) patients treated with direct acting antivirals (DAAs) became an issue. However, its frequency has been poorly estimated, due to the varying definitions used and evaluation of heterogeneous study populations, including those concurrently treated for HBV. METHODS: We prospectively followed HBV surface antigen (HBsAg)-positive Egyptians undergoing interferon-free DAAs, to estimate the risk of HBV reactivation and HBV-related hepatitis...
May 8, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29737218/the-current-situation-and-challenges-of-screening-for-and-treating-hepatitis-b-in-sub-saharan-africa
#15
Charles Béguelin, Fatou Fall, Moussa Seydi, Gilles Wandeler
Hepatitis B virus (HBV) infection is the most important cause of hepatocellular carcinoma in sub-Saharan Africa (SSA). Although the tools to curb the epidemic are known, only a minority of HBV-infected persons are currently diagnosed and treated. Areas covered: We discuss HBV epidemiological trends in SSA, describe important determinants of its natural history, and summarize current knowledge on the continuum of HBV care. Using the results of a systematic review of the literature, we describe the proportion of patients with liver fibrosis at presentation for care...
May 8, 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29736828/the-impact-of-tumor-differentiation-on-the-prognosis-of-hbv-associated-solitary-hepatocellular-carcinoma-following-hepatectomy-a-propensity-score-matching-analysis
#16
Junyi Shen, Jiaye Liu, Chuan Li, Tianfu Wen, Lvnan Yan, Jiayin Yang
AIM: The role of tumor differentiation in the prognosis of hepatocellular carcinoma (HCC) after hepatectomy remains controversial. The present study aimed to classify the impact of tumor differentiation on solitary hepatitis B viral (HBV)-associated HCC using propensity score matching analysis. METHODS: Between January 2009 and March 2015, the data of 721 HCC patients in West China Hospital were prospectively collected and analyzed. Propensity matching analysis was applied to overcome the imbalance in baseline characteristics...
May 7, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29734473/treatment-for-hepatitis-c-virus-associated-mixed-cryoglobulinaemia
#17
REVIEW
Nuria Montero, Alexandre Favà, Eva Rodriguez, Clara Barrios, Josep M Cruzado, Julio Pascual, Maria Jose Soler
BACKGROUND: Hepatitis C virus (HCV)-associated mixed cryoglobulinaemia is the manifestation of an inflammation of small and medium-sized vessels produced by a pathogenic IgM with rheumatoid factor activity generated by an expansion of B-cells. The immune complexes formed precipitate mainly in the skin, joints, kidneys or peripheral nerve fibres. Current therapeutic approaches are aimed at elimination of HCV infection, removal of cryoglobulins and also of the B-cell clonal expansions. The optimal treatment for it has not been established...
May 7, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29732986/intensification-of-antiviral-therapy-for-chronic-hepatitis-b-with-autoleukocyte-immunization
#18
Oleksandr B Herasun
INTRODUCTION: The article presents a new method of intensification of antiviral therapy for chronic hepatitis B with intradermal autoleukocyte immunization during treatment with a drug of nucleotide analogues - tenofovir (patent UA 113873 U, 2017); other curative vaccines for chronic hepatitis B are also regarded. OBJECTIVE: The research involves patients with chronic hepatitis B (30), whose replication of HBV DNA decreased to a certain level after long-lasting (over 2 years) antiviral therapy, its further reduction ceased...
May 6, 2018: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
https://www.readbyqxmd.com/read/29726399/diagnostic-dilemma-for-low-viremia-with-significant-fibrosis-is-hbv-dna-threshold-level-a-good-indicator-for-predicting-liver-damage
#19
Ercan Yenilmez, Rıza Aytaç Çetinkaya, Ersin Tural
BACKGROUND: The most important difficulties about management of hepatitis B are still determining the liver damage and the right time to start antiviral therapy. AIMS: To reveal the role of hepatitis B virus DNA threshold level for prediction of liver fibrosis and inflammation in young-aged hepatitis B e antigen negative chronic hepatitis B patients. STUDY DESIGN: Diagnostic accuracy study. METHODS: A total of 273 hepatitis B e antigen negative young chronic hepatitis B patients with any hepatitis B virus DNA levels between 2008 and 2016, who had liver biopsy after at least 6 months follow up period, enrolled in this retrospective study...
May 4, 2018: Balkan Medical Journal
https://www.readbyqxmd.com/read/29725560/fatal-fulminant-hepatitis-from-rituximab-induced-hepatitis-b-reactivation-in-a-patient-with-follicular-lymphoma-a-case-report-and-a-brief-review-of-literature
#20
Zarak H Khan, Kamran Ilyas, Haider Ghazanfar, Hamza H Khan, Qulsoom Hussain, Sahla Hammad, Ahmed Munir, Rizwan Asim
The objective of our study was to recognize hepatitis B reactivation as a complication of rituximab chemotherapy and to realize the importance of screening for prior Hepatitis B virus (HBV) exposure in all patients with hematologic malignancies who will receive rituximab as part of their therapy. Rituximab is a monoclonal antibody targeting CD 20 receptors on the membrane of B cells. In this case report, we described a 79-year-old man who presented to our department with nausea, fatigue, and jaundice. Two months ago, he had received the last dose of the chemotherapy regimen containing rituximab for follicular B cell lymphoma...
March 2, 2018: Curēus
keyword
keyword
32508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"